Cargando…
The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting ca...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733886/ https://www.ncbi.nlm.nih.gov/pubmed/31552177 http://dx.doi.org/10.3389/fonc.2019.00852 |
_version_ | 1783450046864293888 |
---|---|
author | Chen, Xi Xu, Zhijie Zeng, Shuangshuang Wang, Xiang Liu, Wanli Qian, Long Wei, Jie Yang, Xue Shen, Qiuying Gong, Zhicheng Yan, Yuanliang |
author_facet | Chen, Xi Xu, Zhijie Zeng, Shuangshuang Wang, Xiang Liu, Wanli Qian, Long Wei, Jie Yang, Xue Shen, Qiuying Gong, Zhicheng Yan, Yuanliang |
author_sort | Chen, Xi |
collection | PubMed |
description | Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting cancer progression. Alone or in combination treatments, studies have shown that NM attenuates various malignant tumors, including pancreatic, colorectal, gastric, gallbladder, and hepatocellular cancers. In this review, based on several activating pathways, including the canonical Nuclear factor-κB (NF-κB) signaling pathway, tumor necrosis factor receptor-1 (TNFR1) signaling pathway, and tumorigenesis-related tryptase secreted by mast cells, we summarize the anticancer properties of NM in existing studies both in vitro and in vivo. In addition, the efficacy and side effects of NM in cancer patients are summarized in detail. To further clarify NM's antitumor activities, clinical trials devoted to validating the clinical applications and underlying mechanisms are needed in the future. |
format | Online Article Text |
id | pubmed-6733886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67338862019-09-24 The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications Chen, Xi Xu, Zhijie Zeng, Shuangshuang Wang, Xiang Liu, Wanli Qian, Long Wei, Jie Yang, Xue Shen, Qiuying Gong, Zhicheng Yan, Yuanliang Front Oncol Oncology Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting cancer progression. Alone or in combination treatments, studies have shown that NM attenuates various malignant tumors, including pancreatic, colorectal, gastric, gallbladder, and hepatocellular cancers. In this review, based on several activating pathways, including the canonical Nuclear factor-κB (NF-κB) signaling pathway, tumor necrosis factor receptor-1 (TNFR1) signaling pathway, and tumorigenesis-related tryptase secreted by mast cells, we summarize the anticancer properties of NM in existing studies both in vitro and in vivo. In addition, the efficacy and side effects of NM in cancer patients are summarized in detail. To further clarify NM's antitumor activities, clinical trials devoted to validating the clinical applications and underlying mechanisms are needed in the future. Frontiers Media S.A. 2019-09-03 /pmc/articles/PMC6733886/ /pubmed/31552177 http://dx.doi.org/10.3389/fonc.2019.00852 Text en Copyright © 2019 Chen, Xu, Zeng, Wang, Liu, Qian, Wei, Yang, Shen, Gong and Yan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chen, Xi Xu, Zhijie Zeng, Shuangshuang Wang, Xiang Liu, Wanli Qian, Long Wei, Jie Yang, Xue Shen, Qiuying Gong, Zhicheng Yan, Yuanliang The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications |
title | The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications |
title_full | The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications |
title_fullStr | The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications |
title_full_unstemmed | The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications |
title_short | The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications |
title_sort | molecular aspect of antitumor effects of protease inhibitor nafamostat mesylate and its role in potential clinical applications |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733886/ https://www.ncbi.nlm.nih.gov/pubmed/31552177 http://dx.doi.org/10.3389/fonc.2019.00852 |
work_keys_str_mv | AT chenxi themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT xuzhijie themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT zengshuangshuang themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT wangxiang themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT liuwanli themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT qianlong themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT weijie themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT yangxue themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT shenqiuying themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT gongzhicheng themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT yanyuanliang themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT chenxi molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT xuzhijie molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT zengshuangshuang molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT wangxiang molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT liuwanli molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT qianlong molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT weijie molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT yangxue molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT shenqiuying molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT gongzhicheng molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications AT yanyuanliang molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications |